Tilray Brands (TLRY) Net Equity Issued and Repurchased (2020 - 2026)
Tilray Brands' (TLRY) quarterly Net Equity Issued and Repurchased came in at $84.9 million in Q2 2026, up 295.88% YoY from $21.4 million in Q2 2025, and up 67.93% on a QoQ basis from $50.6 million in Q4 2025.
Tilray Brands (TLRY) Net Equity Issued and Repurchased (2020 - 2026) Analysis & Trends
Tilray Brands (TLRY) has 5 years of Net Equity Issued and Repurchased data on file, last reported at $84.9 million in Q2 2026.
- Quarterly Net Equity Issued and Repurchased rose 295.88% year-over-year to $84.9 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $158.0 million (up 3370.01% YoY) and the FY2026 annual result came in at $158.0 million, down 1.99% from the prior year.
- Net Equity Issued and Repurchased rose to $84.9 million in Q2 2026, from $50.6 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $262.5 million in Q2 2022 to a low of -$121.0 million in Q2 2024.
- A 4-year average of $60.6 million and a median of $50.6 million in 2025 frame the typical range for Net Equity Issued and Repurchased.
- Annual changes were most pronounced in 2025 — Net Equity Issued and Repurchased sank 66.16% — and 2026, when it soared 295.88%.
- Tracing TLRY's Net Equity Issued and Repurchased over 4 years: stood at $129.6 million in 2022, then sank by 48.71% to $66.5 million in 2024, then decreased by 23.93% to $50.6 million in 2025, then soared by 67.93% to $84.9 million in 2026.
- The last three Net Equity Issued and Repurchased figures came in at $84.9 million (Q2 2026), $50.6 million (Q4 2025), and $22.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | - |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 700,000.00 |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 84.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Tilray Brands | 541.05 Mn | 306.41 Mn | 90.52 Mn | 84.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 84.92 Mn |
| May 31, 2026 | 84.92 Mn |
| Nov 30, 2025 | 50.57 Mn |
| Nov 30, 2025 | 50.57 Mn |
| Aug 31, 2025 | 22.49 Mn |
| Aug 31, 2025 | 22.49 Mn |
| May 31, 2025 | 21.45 Mn |
| May 31, 2025 | 21.45 Mn |
| Feb 28, 2025 | 28.22 Mn |
| Feb 28, 2025 | 28.22 Mn |
| Aug 31, 2024 | 66.47 Mn |
| Aug 31, 2024 | 66.47 Mn |
| May 31, 2024 | -120.97 Mn |
| May 31, 2024 | -120.97 Mn |
| Aug 31, 2022 | 129.59 Mn |
| Aug 31, 2022 | 129.59 Mn |
| May 31, 2022 | 262.51 Mn |
| May 31, 2022 | 262.51 Mn |
| Nov 30, 2020 | 102.82 Mn |
| Nov 30, 2020 | 102.82 Mn |